Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

inflammatory conditions

- PMLiVE

Pfizer appoints chief scientific officer

Dr Ole Isacson will lead the neuroscience research unit

AstraZeneca AZ global R&D corporate HQ

AZ slims down again with sale of antibiotics to Pfizer

Deal does not include biologic anti-infective products from Medimmune unit

- PMLiVE

NICE backs Xalkori for lung cancer, but may cut two others from CDF

Preliminary verdict could lead to removal of Novartis' Afinitor and Janssen's Imbruvica from the Fund

- PMLiVE

Pfizer rides out Sanofi and confirms $14bn Medivation takeover

Success of cancer specialist’s drug Xtandi followed by work on other cancer drugs

- PMLiVE

J&J is to appeal Remicade patent ruling in US

As Pfizer is poised to bring biosimilar version to market

Eli Lilly HQ

Lilly presses on with breast cancer study despite setback

CDK 4/6 inhibitor abemaciclib shows disappointing results in phase III trial

- PMLiVE

Allergies and asthma

Reframing the conversation from disease burden to prevention and health promotion

- PMLiVE

Fertility drugs drive healthcare growth at Merck KGaA

Strong performances from Gonal-f and Rebif boost the firm’s 2016 sales forecast

Novartis Gehry Building

FDA deems ribociclib a breast cancer breakthrough

Novartis looks to catch-up with Pfizer’s Ibrance with early approval in the US

Biogen Idec building

Biogen buys into Ionis’ nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

- PMLiVE

Controversial new CDF promises “clearer, faster decision-making”

However, pharma companies and charities remain concerned over pricing and access

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links